Spero Therapeutics, Inc.
$2.84
▼
-0.82%
2026-04-21 09:34:01
sperotherapeutics.com
NMS: SPRO
Explore Spero Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$164.41 M
Current Price
$2.84
52W High / Low
$3.22 / $0.57
Stock P/E
19.18
Book Value
$1.05
Dividend Yield
—
ROCE
11.92%
ROE
16.3%
Face Value
—
EPS
$0.15
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
25
Beta
1.45
Debt / Equity
4.91
Current Ratio
7.59
Quick Ratio
7.59
Forward P/E
-2.41
Price / Sales
2.31
Enterprise Value
$117.2 M
EV / EBITDA
16.37
EV / Revenue
1.75
Rating
None
Target Price
$4
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | DiaMedica Therapeutics Inc. | $6.56 | — | $369.1 M | — | -61.16% | -67.68% | $10.42 / $3.28 | $1.04 |
| 2. | MetaVia Inc. | $1.51 | — | $7.13 M | — | -250.37% | -1.96% | $19.03 / $1.17 | $2.31 |
| 3. | Tiziana Life Sciences Ltd | $1.21 | — | $143.81 M | — | -401.27% | -2.32% | $2.6 / $0.87 | $0.08 |
| 4. | Cullinan Therapeutics, Inc. | $14.52 | — | $911.52 M | — | -58.85% | -44.02% | $16.74 / $5.68 | $6.79 |
| 5. | OnKure Therapeutics, Inc. | $4.99 | — | $68.37 M | — | -112.02% | -74.39% | $5.06 / $1.7 | $4.11 |
| 6. | Trevi Therapeutics, Inc. | $15.4 | — | $1.96 B | — | -26.85% | -30.23% | $15.76 / $5.38 | $1.43 |
| 7. | XORTX Therapeutics Inc. | $2.25 | — | $4.16 M | — | -156.2% | -98% | $9.85 / $2.42 | $0.3 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 39.66 M | 3.05 M | 11.8 M | 5.11 M | 9.36 M | — |
| Operating Profit | 31.41 M | -7.33 M | -2.36 M | -14.56 M | -20.85 M | — |
| Net Profit | 31.52 M | -7.38 M | -1.7 M | -13.87 M | -20.89 M | — |
| EPS in Rs | 0.54 | -0.13 | -0.03 | -0.24 | -0.36 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 59.62 M | 27.4 M | 96.73 M | 48.58 M |
| Operating Profit | 7.16 M | -72.48 M | 26.79 M | -30.57 M |
| Net Profit | 8.57 M | -68.57 M | 22.81 M | -46.41 M |
| EPS in Rs | 0.15 | -1.18 | 0.39 | -0.8 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 68.92 M | 110.54 M | 182.39 M | 124.8 M |
| Total Liabilities | 9.9 M | 64.42 M | 75.5 M | 48.87 M |
| Equity | 59.02 M | 46.12 M | 106.89 M | 75.93 M |
| Current Assets | 67.29 M | 107.28 M | 131.21 M | 113.57 M |
| Current Liabilities | 8.87 M | 49.07 M | 37.15 M | 21.65 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -12.62 M | -23.44 M | -32.99 M | -7.73 M |
| Investing CF | — | — | 0 M | 33.81 M |
| Financing CF | — | 0 M | 0.22 M | -29.55 M |
| Free CF | -12.62 M | -23.44 M | -32.99 M | -7.73 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -71.68% | 99.13% | — | — |
| Earnings Growth % | -400.65% | 149.13% | — | — |
| Profit Margin % | -250.28% | 23.58% | -95.55% | — |
| Operating Margin % | -264.58% | 27.69% | -62.92% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -264.57% | 28.07% | -88.39% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.